Ibutamoren mesylate by Lumos Pharma for Born Small For Gestational Age (SGA): Likelihood of Approval

Ibutamoren mesylate is under clinical development by Lumos Pharma and currently in Phase I for Born Small For Gestational Age (SGA). According to GlobalData, Phase I drugs for Born Small For Gestational Age (SGA) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ibutamoren mesylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ibutamoren mesylate overview

Ibutamoren mesylate (MK-677) is under development for the treatment of pediatric growth hormone deficiency (PGHD), Turner syndrome, children born small for gestational age (SGA), idiopathic short stature, nonalcoholic fatty liver disease (NAFLD) and Prader Willi syndrome. It is administered orally. MK-0677 is a synthetic GHRS, ghrelin mimetic compound. MK-0677 is active growth hormone secretagogue that acts on the growth hormone secretagogue receptor in the anterior pituitary to stimulate the release of growth hormone. It was under development for the treatment of Alzheimer’s disease, fibromyalgia, sarcopenia in post-hip fracture patients and chronic renal failure in end-stage renal disease patients.

Lumos Pharma overview

Lumos Pharma, formerly NewLink Genetics is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of new therapies for the treatment of unmet medical needs of rare diseases. The company’s lead investigating candidate, LUM-201 (ibutamoren) is an oral growth hormone stimulating therapy for the treatment of pediatric growth hormone deficiency (PGHD), turner syndrome, children born small for gestational age (SGA), and other rare endocrine disorders. Lumos Pharma is headquartered in Austin, Texas, the US.

For a complete picture of Ibutamoren mesylate’s drug-specific PTSR and LoA scores, buy the report here.